GlassScriptPhysician profile
Danisette Torres
NPI 1457912792
$371.99
in general payments reported to CMS, 2019-2025
9 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $16.39 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $75.30 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $72.02 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $53.09 | 2025 | |
| Lundbeck LLC | $34.30 | 2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $32.46 | 2025 | |
| Janssen Biotech, INC. | $29.67 | 2025 | |
| Ucb, INC. | $26.38 | 2025 | Rystiggo |
| Pfizer INC. | $25.63 | 2025 | |
| Merz Pharmaceuticals, LLC | $23.14 | 2025 | Xeomin, Ampyra, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danisette Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.